2022
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDuloxetine HydrochlorideHumansMiceNeurotoxicity SyndromesOxaliplatinPeripheral Nervous System DiseasesConceptsDRG neuronsPeripheral neurotoxicitySide effectsOxaliplatin-Induced Peripheral NeurotoxicityOxaliplatin-based regimensOxaliplatin-based treatmentPharmacokinetics of oxaliplatinEffect of duloxetineMouse DRG neuronsWild-type miceCytotoxicity of oxaliplatinConcentration-dependent mannerColorectal cancerCancer patientsPlasma levelsOIPNPlasma pharmacokineticsDuloxetinePrevention strategiesTherapeutic candidateOxaliplatinTumor cell linesTranslational feasibilityMiceComplete protection
2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2014
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Hershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.Peer-Reviewed Original ResearchMeSH KeywordsAdultAminesAmitriptylineAnalgesicsAnticonvulsantsAntidepressive Agents, TricyclicAntineoplastic AgentsBaclofenComorbidityCyclohexanecarboxylic AcidsDrug Therapy, CombinationDuloxetine HydrochlorideEvidence-Based MedicineGabapentinGamma-Aminobutyric AcidGelsHumansIncidenceKetamineNeoplasmsNeuralgiaPeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSurvivorsThiophenesTreatment OutcomeUnited StatesConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyPrimary outcomePrevention of CIPNTreatment of CIPNClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineNeuropathic pain conditionsSeverity of neuropathyClinical practice guidelinesPatient-reported outcomesAdult cancer survivorsQuality of lifeSystematic literature searchEvidence-based guidanceDifferent time pointsPain conditionsCancer survivorsTreatment optionsTricyclic antidepressantsPractice guidelinesAdult cancersNeurophysiologic changesEligibility criteriaTreatment approaches